- Cytokinetics, Incorporated stock price today and history
Cytokinetics, Incorporated (CYTK) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Cytokinetics, Incorporated stock price
Cytokinetics, Incorporated latest news:
Cytokinetics Crumbles on Late-Stage Results
Cytokinetics shares drop 31% on late-stage ALS drug failure
Cytokinetics Inc. shares dropped 31% in premarket trade Tuesday after the company said its lead product candidate failed to meet primary or secondary endpoints in a late-stage clinical trial. The drug, tirasemtiv, was being developed for the progressive neurodegenerative disease amyotrophic lateral sclerosis (ALS); Cytokinetics said on Tuesday that it plans to suspend tirasemtiv's development. The company said it believes tirasemtiv's limitations "may be addressed with our next-generation fast skeletal muscle activator, CK-2127107," which is currently in mid-stage clinical trials, with phase 2 results expected next year. CK-212710, which is also called CK-107, is being developed to improve muscle function and physical performance for individuals with ALS, spinal muscular atrophy, chronic obstructive pulmonary disease and for elderly adults with limited mobility. Cytokinetics shares have declined 11.6% over the last three months, compared with a 6.3% rise in the S&P 500 and a 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Cytokinetics reports Q3 loss of $0.60/shr
* Cytokinetics, Inc. reports third quarter 2017 financial
Cytori Therapeutics IncCYTX
Daily 2X VIX Med-Term ETN VelocitysharesTVIZ
Daily 2X VIX ST ETN VelocitysharesTVIX
Daily Inverse VIX Mt ETN VelocitysharesZIV
Daily Inverse VIX ST ETN VelocitysharesXIV
Daily Journal Corp. (S.C.)DJCO